Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06831136RecruitingPhase 2
Endoscopic ultrasound ablation plus immunotherapy for pancreatic cancer
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Houston, TexasAges 18 years+ - NCT06831149RecruitingPhase 2
Spy imaging to reduce fistulas after throat reconstruction
This study is testing a special imaging tool (SPY system) that helps surgeons see blood flow better during surgery to rebuild the throat. The goal is to reduce the risk of fluid leaks (fistulas) after the operation.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Aurora, ColoradoAges 1–39 - NCT06840002RecruitingPhase 1/Phase 2
Targeted drug plus chemotherapy for recurrent ovarian cancer
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06849180Recruiting
Personalized Treatment for Advanced Combined Liver Cancer
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
Nanjing, JiangsuAges 18 years+ - NCT06850103RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced rectal cancer that has spread a little
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06850753Recruiting
En bloc removal of liver and pancreas with transplant for bile duct cancer
This trial tests a new surgical approach that removes the liver, pancreas, and bile duct all at once (and then gives a liver transplant) for people with a type of bile duct cancer that cannot be removed with standard surgery. It may help people whose cancer is limited to the liver area and who have not responded to other treatments.
OsloAges 18–70 - NCT06853496RecruitingPhase 1
RK-582 for advanced colorectal cancer
This trial tests a new type of pill called RK-582 that may help block the growth of colorectal cancer cells. It is for people whose cancer has spread and hasn't gotten better with other treatments.
Koto-ku, TokyoAges 18 years+ - NCT06855069RecruitingPhase 3
A study of HS-20089 for platinum-resistant ovarian cancer
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
BeijingAges 18 years+ - NCT06859203Recruiting
PET scan study for men with rising PSA after prostate cancer treatment
This study tests a newer type of PET scan (fluciclovine) in men whose previous PSMA PET scan was negative or unclear. It aims to find if the fluciclovine PET can better detect where the cancer has returned, helping guide treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06862856Recruiting
PET Scan for Men With Very Low PSA After Prostate Surgery
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06863233RecruitingPhase 1
Immune cell imaging study for people with lung cancer
This study uses an imaging method to look at certain immune cells (CD8+ T cells) in people with advanced non-small cell lung cancer who are about to receive a new cell therapy. It helps researchers understand how the immune system responds during treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT06865664RecruitingPhase 1
Engineered immune cells for relapsed rhabdomyosarcoma in youth
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Bethesda, MarylandAges 3–39 - NCT06867445Recruiting
Minimally invasive surgery for recurrent cervical or vaginal cancer
This trial tests a minimally invasive surgery (using small incisions) to remove a pelvic tumor that has come back after treatment for vaginal or cervical cancer. It aims to see if this approach can safely remove the recurrence while avoiding more extensive surgery.
RomeAges 18 years+ - NCT06867822RecruitingPhase 1
Testing ProAgio for Advanced Colorectal Cancer
This trial tests a new drug called ProAgio for people with advanced or metastatic colorectal cancer. It aims to see if ProAgio can help shrink or slow the cancer when combined with standard treatments.
Birmingham, AlabamaAges 19 years+ - NCT06869603Recruiting
Mediterranean diet for recurrent kidney stones and bone health
This trial looks at whether following the Mediterranean diet helps people who get kidney stones over and over again. It also checks how diet affects bone health. If you have had multiple kidney stones, you may be able to join.
NaplesAges 18 years+ - NCT06870942RecruitingPhase 2
Radiation therapy for liver cancer that progresses after first immunotherapy
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06883396Recruiting
Looking at why MPFL knee surgery fails
This study looks at why some people's kneecaps keep dislocating after a specific type of surgery (MPFL reconstruction). It aims to find risk factors that might cause the surgery to not work as well.
Redwood City, CaliforniaAges 10–35 - NCT06886516RecruitingEarly Phase 1
Blood thinner study for cancer patients with low platelets
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
Boston, MassachusettsAges 18 years+ - NCT06888063RecruitingPhase 2
Chemo pump into the liver for bile duct cancer that can be surgically removed
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
Rotterdam, South HollandAges 18 years+ - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Augusta, GeorgiaAges 18 years+ - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,384 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.